sf-837 and Diarrhea

sf-837 has been researched along with Diarrhea* in 1 studies

Other Studies

1 other study(ies) available for sf-837 and Diarrhea

Article	Year
A survey of the side effects of midecamycin acetate (Miocamycin) dry syrup after marketing. International journal of clinical pharmacology, therapy, and toxicology, 1990, Volume: 28, Issue:6 Three-year post-marketing surveillance (PMS) on midecamycin acetate dry syrup from July, 1985 through April, 1988 resulted in collection of reports on 12,169 patients. Among these, a total of 66 patients (0.54%) with side effects were reported. The main side effects caused by this drug were gastrointestinal and skin appendages disorders. They included diarrhea, abdominal pain, eruption and others. Side effects, which had not been observed up to the approval were itchiness and multiple erythema. None of these side effects were serious. When the drug was administered to 26 patients hypersensitive to beta-lactam agents, no allergy symptoms developed. Based on these results, midecamycin acetate dry syrup can be evaluated to be a highly safe macrolide in clinical use. Topics: Adolescent; Adult; Child; Child, Preschool; Diarrhea; Dosage Forms; Female; Humans; Infant; Infant, Newborn; Leucomycins; Male; Middle Aged; Product Surveillance, Postmarketing; Skin Diseases	1990

Article

Year

A survey of the side effects of midecamycin acetate (Miocamycin) dry syrup after marketing.

International journal of clinical pharmacology, therapy, and toxicology, 1990, Volume: 28, Issue:6

Three-year post-marketing surveillance (PMS) on midecamycin acetate dry syrup from July, 1985 through April, 1988 resulted in collection of reports on 12,169 patients. Among these, a total of 66 patients (0.54%) with side effects were reported. The main side effects caused by this drug were gastrointestinal and skin appendages disorders. They included diarrhea, abdominal pain, eruption and others. Side effects, which had not been observed up to the approval were itchiness and multiple erythema. None of these side effects were serious. When the drug was administered to 26 patients hypersensitive to beta-lactam agents, no allergy symptoms developed. Based on these results, midecamycin acetate dry syrup can be evaluated to be a highly safe macrolide in clinical use.

Topics: Adolescent; Adult; Child; Child, Preschool; Diarrhea; Dosage Forms; Female; Humans; Infant; Infant, Newborn; Leucomycins; Male; Middle Aged; Product Surveillance, Postmarketing; Skin Diseases

1990